FDA Green Lights Generic Namenda for Dementia

Share this content:
FDA approves new drug application for generic Namenda from Upsher-Smith.
FDA approves new drug application for generic Namenda from Upsher-Smith.

Drug-maker Upsher-Smith announced that the FDA has approved its abbreviated new drug application (ANDA) for memantine HCl Tablets, the generic version of Actavis' Namenda.

Namenda is an NMDA (N-methyl-D-aspartate) inhibitor indicated for the treatment of moderate to severe dementia of the Alzheimer's type. It is presumed to work as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels.

Memantine HCl Tablets will be available in 5mg and 10mg strengths.

For more information call (888) 650-3789 or visit Upsher-Smith.com.

You must be a registered member of Psychiatry Advisor to post a comment.

Sign Up for Free e-newsletters